Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776289 | 0.88 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL23185880 | 0.87 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL3774389 | 0.87 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL3769585 | 0.85 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL30914985 | 0.85 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL31737239 | 0.84 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL30915072 | 0.84 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL17762744 | 0.83 | MAPT (0.53) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL4062890 | 0.83 | GPR119 (0.61) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL3782855 | 0.82 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-3067346-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9409890-B2 | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARAMCEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2640709-B1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2012068109-A2 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.